MedWatch

Reapplix starts company in Texas and gears up for US launch of diabetes patch

Danish company Reapplix has presented new, good data for a biological patch that heals diabetic foot ulcers, and the company has therefore established a subsidiary in the US, which will be in charge of launching the product on the US market. At the same time, the company has hired a CFO and has secured more funding from its investors, including Novo Holdings, Seed Capital and Vækstfonden.

Foto: Reapplix/PR

Before long, Danish company Reapplix will be ready to launch its main asset - a special biological patch for hard-to-heal ulcers - on the important US market. The company has therefore established a subsidiary company in Texas in the Southern US, which will spearhead the upcoming launch.

At the same time, the company has presented good clinical results for the patch in treatment of diabetic foot ulcers at the annual meeting in American Diabetes Association (ADA), which was held in Orlando recently.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Coloplasts nye skattedetaljer viser enorme nationale forskelle - Danmark blandt de laveste skatteopkrævere

Mens Coloplast betaler godt 20 pct. i effektiv skattesats herhjemme, lægger medicoselskabet næsten 40 pct. i skatteposen af sit overskud i Frankrig, viser nye detaljerede skatteoplysninger fra virksomheden. Størstedelen af medicoselskabets ansatte arbejder i Ungarn, hvor firmaet også betaler den laveste selskabsskat på bare 15 pct, men produktionen er lagt i landet af en række andre årsager, fortæller Coloplast.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier